Skip to main content

A randomized phase II trial of cetuximab-based induction chemotherapy followed by concurrent cetuximab, 5-FU, hydroxyurea, and hyperfractionated radiation (CetuxFHX), or cetuximab, cisplatin, and accelerated radiation with concomitant boost (CetuxPX) in patients with locoregionally advanced head and neck cancer (HNC).

Publication ,  Conference
Seiwert, TY; Haraf, DJ; Cohen, EE; Blair, EA; Stenson, K; Salama, JK; Kocherginsky, M; Villaflor, VM; Witt, M; Williams, R; Dekker, A; Vokes, EE
Published in: Journal of Clinical Oncology
May 20, 2011

Duke Scholars

Published In

Journal of Clinical Oncology

DOI

EISSN

1527-7755

ISSN

0732-183X

Publication Date

May 20, 2011

Volume

29

Issue

15_suppl

Start / End Page

5519 / 5519

Publisher

American Society of Clinical Oncology (ASCO)

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Seiwert, T. Y., Haraf, D. J., Cohen, E. E., Blair, E. A., Stenson, K., Salama, J. K., … Vokes, E. E. (2011). A randomized phase II trial of cetuximab-based induction chemotherapy followed by concurrent cetuximab, 5-FU, hydroxyurea, and hyperfractionated radiation (CetuxFHX), or cetuximab, cisplatin, and accelerated radiation with concomitant boost (CetuxPX) in patients with locoregionally advanced head and neck cancer (HNC). In Journal of Clinical Oncology (Vol. 29, pp. 5519–5519). American Society of Clinical Oncology (ASCO). https://doi.org/10.1200/jco.2011.29.15_suppl.5519
Seiwert, T. Y., D. J. Haraf, E. E. Cohen, E. A. Blair, K. Stenson, J. K. Salama, M. Kocherginsky, et al. “A randomized phase II trial of cetuximab-based induction chemotherapy followed by concurrent cetuximab, 5-FU, hydroxyurea, and hyperfractionated radiation (CetuxFHX), or cetuximab, cisplatin, and accelerated radiation with concomitant boost (CetuxPX) in patients with locoregionally advanced head and neck cancer (HNC).” In Journal of Clinical Oncology, 29:5519–5519. American Society of Clinical Oncology (ASCO), 2011. https://doi.org/10.1200/jco.2011.29.15_suppl.5519.
Seiwert TY, Haraf DJ, Cohen EE, Blair EA, Stenson K, Salama JK, Kocherginsky M, Villaflor VM, Witt M, Williams R, Dekker A, Vokes EE. A randomized phase II trial of cetuximab-based induction chemotherapy followed by concurrent cetuximab, 5-FU, hydroxyurea, and hyperfractionated radiation (CetuxFHX), or cetuximab, cisplatin, and accelerated radiation with concomitant boost (CetuxPX) in patients with locoregionally advanced head and neck cancer (HNC). Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2011. p. 5519–5519.

Published In

Journal of Clinical Oncology

DOI

EISSN

1527-7755

ISSN

0732-183X

Publication Date

May 20, 2011

Volume

29

Issue

15_suppl

Start / End Page

5519 / 5519

Publisher

American Society of Clinical Oncology (ASCO)

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences